دورية أكاديمية
أعرض في EDS

Cancer to Cataracts: The Mechanistic Impact of Aldo-Keto Reductases in Chronic Diseases.

التفاصيل البيبلوغرافية
العنوان: Cancer to Cataracts: The Mechanistic Impact of Aldo-Keto Reductases in Chronic Diseases.
المؤلفون: Shanbhag AP; Bugworks Research India Pvt. Ltd., Bengaluru, Karnataka, India.; Novartis Healthcare Pvt. Ltd., Hyderabad, Telangana, India., Bhowmik P; Bugworks Research India Pvt. Ltd., Bengaluru, Karnataka, India.; Centre for Cellular and Molecular Platforms (C-CAMP), National Centre for Biological Sciences (NCBS), Bengaluru, Karnataka, India.
المصدر: The Yale journal of biology and medicine [Yale J Biol Med] 2024 Jun 28; Vol. 97 (2), pp. 179-204. Date of Electronic Publication: 2024 Jun 28 (Print Publication: 2024).
نوع المنشور: Journal Article; Review
اللغة: English
بيانات الدورية: Publisher: Yale Journal of Biology and Medicine Country of Publication: United States NLM ID: 0417414 Publication Model: eCollection Cited Medium: Internet ISSN: 1551-4056 (Electronic) Linking ISSN: 00440086 NLM ISO Abbreviation: Yale J Biol Med Subsets: MEDLINE
أسماء مطبوعة: Original Publication: New Haven, CT : Yale Journal of Biology and Medicine
مواضيع طبية MeSH: Aldo-Keto Reductases*/metabolism , Aldo-Keto Reductases*/genetics , Cataract*/enzymology , Cataract*/genetics , Cataract*/metabolism , Neoplasms*/enzymology , Neoplasms*/genetics, Humans ; Chronic Disease
مستخلص: Aldo-keto reductases (AKRs) are a superfamily of promiscuous enzymes that have been chiseled by evolution to act as catalysts for numerous regulatory pathways in humans. However, they have not lost their promiscuity in the process, essentially making them a double-edged sword. The superfamily is involved in multiple metabolic pathways and are linked to chronic diseases such as cataracts, diabetes, and various cancers. Unlike other detoxifying enzymes such as cytochrome P450s (CYP450s), short-chain dehydrogenases (SDRs), and medium-chain dehydrogenases (MDRs), that participate in essential pathways, AKRs are more widely distributed and have members with interchangeable functions. Moreover, their promiscuity is ubiquitous across all species and participates in the resistance of pathogenic microbes. Moreover, the introduction of synthetic substrates, such as synthetic molecules and processed foods, results in unwanted "toxification" due to enzyme promiscuity, leading to chronic diseases.
(Copyright ©2024, Yale Journal of Biology and Medicine.)
References: Chem Biol Interact. 2011 May 30;191(1-3):234-8. (PMID: 21276783)
J Agric Food Chem. 2019 Jul 31;67(30):8382-8392. (PMID: 31271032)
Chem Biol Interact. 2003 Feb 1;143-144:325-32. (PMID: 12604219)
Chem Biol Interact. 2015 Jun 5;234:236-46. (PMID: 25304492)
Int J Mol Sci. 2021 Nov 26;22(23):. (PMID: 34884615)
Steroids. 2011 Apr;76(5):484-90. (PMID: 21255593)
Front Pharmacol. 2012 Aug 02;3:148. (PMID: 22876234)
PLoS Genet. 2016 Oct 7;12(10):e1006305. (PMID: 27716796)
Cancer Res. 2004 Oct 15;64(20):7610-7. (PMID: 15492289)
Front Microbiol. 2017 Oct 11;8:2006. (PMID: 29075254)
J Ophthalmol. 2010;2010:521204. (PMID: 20628518)
Genome Biol. 2005;6(1):R2. (PMID: 15642094)
Exp Dermatol. 2014 Aug;23(8):573-8. (PMID: 24917395)
Chem Biol Interact. 2015 Mar 25;230:30-9. (PMID: 25686905)
Curr Drug Targets. 2018;19(1):38-54. (PMID: 28124606)
Biochem J. 2023 Jul 12;480(13):975-997. (PMID: 37335080)
Toxicol Lett. 2008 Sep;181(1):1-6. (PMID: 18616992)
Cell Mol Life Sci. 2008 Dec;65(24):3879-94. (PMID: 19011751)
Diagn Pathol. 2014 Feb 26;9:42. (PMID: 24571686)
Metabolites. 2021 May 21;11(6):. (PMID: 34063865)
Ther Adv Urol. 2015 Dec;7(6):378-87. (PMID: 26622322)
Andrologia. 2013 Oct;45(5):326-31. (PMID: 22970857)
Lung Cancer (Auckl). 2016 May 02;7:53-61. (PMID: 28210161)
Drug Metab Rev. 2008;40(4):553-624. (PMID: 18949601)
Arch Toxicol. 2016 Apr;90(4):753-80. (PMID: 26920149)
FEBS Lett. 2013 Nov 15;587(22):3681-6. (PMID: 24100137)
Int J Mol Sci. 2020 Aug 29;21(17):. (PMID: 32872468)
Chem Biol Interact. 2003 Feb 1;143-144:263-9. (PMID: 12604212)
Int J Clin Oncol. 2016 Jun;21(3):548-56. (PMID: 26573806)
Eur J Pharmacol. 2022 Sep 15;931:175191. (PMID: 35964660)
Metabolites. 2021 Dec 13;11(12):. (PMID: 34940623)
Chem Biol Interact. 2017 Oct 1;276:210-217. (PMID: 28342889)
FEBS Lett. 2018 Mar;592(6):1010-1019. (PMID: 29430658)
FEBS Lett. 2020 Feb;594(3):564-580. (PMID: 31573681)
Toxicology. 2007 Sep 5;238(2-3):111-8. (PMID: 17618725)
Chem Res Toxicol. 2012 Jan 13;25(1):113-21. (PMID: 22053912)
Toxicol Lett. 2004 Mar 14;148(1-2):65-72. (PMID: 15019089)
FEMS Microbiol Lett. 2002 Nov 5;216(2):123-31. (PMID: 12435492)
Bioorg Med Chem. 2014 Oct 1;22(19):5220-33. (PMID: 25182963)
Protein Sci. 2002 Mar;11(3):636-41. (PMID: 11847285)
Antioxidants (Basel). 2024 May 12;13(5):. (PMID: 38790699)
J Biol Chem. 2015 Mar 6;290(10):6531-45. (PMID: 25577493)
Adv Exp Med Biol. 2021;1347:65-82. (PMID: 33945128)
Biochemistry. 2001 Sep 11;40(36):10901-10. (PMID: 11535067)
Front Endocrinol (Lausanne). 2020 Sep 04;11:591. (PMID: 33013692)
Oxid Med Cell Longev. 2019 Aug 5;2019:6175804. (PMID: 31467634)
Chem Biol Interact. 2019 May 1;304:124-130. (PMID: 30849339)
Toxicol In Vitro. 2014 Jun;28(4):707-14. (PMID: 24590062)
Carcinogenesis. 2008 Oct;29(10):1955-62. (PMID: 18632753)
Chem Biol Interact. 2019 May 25;305:21-27. (PMID: 30926318)
Proc Natl Acad Sci U S A. 2024 Feb 13;121(7):e2319840121. (PMID: 38315855)
Biochem J. 2007 Jul 1;405(1):95-105. (PMID: 17381426)
J Steroid Biochem Mol Biol. 2022 Jul;221:106121. (PMID: 35489629)
J Hepatocell Carcinoma. 2021 Aug 30;8:997-1021. (PMID: 34513744)
Biochem J. 2006 Oct 1;399(1):101-9. (PMID: 16787387)
Mol Hum Reprod. 2004 Jul;10(7):527-33. (PMID: 15118078)
AAPS J. 2021 Jan 7;23(1):20. (PMID: 33415501)
J Biol Chem. 2010 Mar 19;285(12):8880-6. (PMID: 20093363)
Adv Exp Med Biol. 2018;1032:173-202. (PMID: 30362099)
Chem Res Toxicol. 2008 May;21(5):1086-94. (PMID: 18402469)
Hum Genomics. 2009 Jul;3(4):362-70. (PMID: 19706366)
FEBS J. 2008 Jun;275(12):3041-50. (PMID: 18445038)
Front Genet. 2017 May 30;8:72. (PMID: 28611826)
PLoS One. 2015 Jul 29;10(7):e0134506. (PMID: 26222439)
FEBS J. 2020 Apr;287(7):1306-1322. (PMID: 31663687)
Front Pharmacol. 2012 Mar 09;3:35. (PMID: 22408622)
Int J Microbiol. 2020 Jun 12;2020:8045646. (PMID: 32612660)
Biochem J. 2000 Oct 1;351(Pt 1):67-77. (PMID: 10998348)
Anticancer Drugs. 2011 Jun;22(5):402-8. (PMID: 21317765)
Endocr Rev. 2020 Apr 1;41(2):. (PMID: 31512725)
Chem Biol Interact. 2011 May 30;191(1-3):192-8. (PMID: 21329684)
Chem Biol Interact. 2003 Feb 1;143-144:621-31. (PMID: 12604248)
Drug Metab Pharmacokinet. 2012;27(5):553-8. (PMID: 22498646)
Chem Res Toxicol. 2005 Feb;18(2):365-74. (PMID: 15720144)
Diabetes Care. 2006 Sep;29(9):2053-7. (PMID: 16936152)
Cell Biosci. 2016 Mar 05;6:18. (PMID: 26949513)
FEBS J. 2007 Jan;274(1):1-22. (PMID: 17222174)
BMC Med Genet. 2010 Mar 31;11:52. (PMID: 20353610)
Chem Biol Interact. 2017 Oct 1;276:182-193. (PMID: 28322781)
Biochem J. 1999 Oct 15;343 Pt 2:487-504. (PMID: 10510318)
Metabolism. 2019 Oct;99:67-80. (PMID: 31330134)
Drug Metab Dispos. 2023 Dec;51(12):1569-1577. (PMID: 37722844)
Endocrinology. 2007 May;148(5):1996-2005. (PMID: 17272390)
J Nat Prod. 2011 May 27;74(5):1201-6. (PMID: 21561086)
Ann N Y Acad Sci. 2009 Feb;1155:33-42. (PMID: 19250190)
J Biol Chem. 2002 Jul 5;277(27):24799-808. (PMID: 11978787)
Brain Res. 2001 Oct 19;916(1-2):229-38. (PMID: 11597610)
Mol Biochem Parasitol. 2010 Oct;173(2):132-41. (PMID: 20595031)
Front Endocrinol (Lausanne). 2015 May 28;6:88. (PMID: 26074879)
Exp Dermatol. 2016 Jan;25(1):38-43. (PMID: 26308156)
Cell Death Discov. 2023 Nov 17;9(1):418. (PMID: 37978169)
Endocr Rev. 2019 Apr 1;40(2):447-475. (PMID: 30137266)
Medicine (Baltimore). 2023 Feb 22;102(8):e33041. (PMID: 36827074)
Hepatology. 2011 Oct;54(4):1322-32. (PMID: 21688283)
Mutat Res. 2009 Mar 9;662(1-2):67-74. (PMID: 19162045)
Chem Biol Interact. 2019 Jul 1;307:186-194. (PMID: 31028727)
Drug Metab Dispos. 2023 Apr;51(4):427-435. (PMID: 36623880)
J Pharmacol Exp Ther. 2010 Dec;335(3):533-45. (PMID: 20837989)
PLoS Comput Biol. 2016 Jan 28;12(1):e1004705. (PMID: 26821166)
Biol Pharm Bull. 2005 Jun;28(6):1075-8. (PMID: 15930748)
Chem Biol Interact. 2001 Jan 30;130-132(1-3):499-525. (PMID: 11306071)
Eur Neuropsychopharmacol. 2012 Sep;22(9):632-40. (PMID: 22356824)
Metabolites. 2021 May 26;11(6):. (PMID: 34073440)
Pharmacol Rev. 2021 Jul;73(3):1150-1171. (PMID: 34312303)
Biol Pharm Bull. 2006 Mar;29(3):539-42. (PMID: 16508162)
Biomolecules. 2023 Apr 18;13(4):. (PMID: 37189435)
Brief Bioinform. 2019 Jul 19;20(4):1085-1093. (PMID: 29447345)
J Biochem. 2017 Nov 1;162(5):371-379. (PMID: 28992312)
Oncotarget. 2016 Jul 26;7(30):48050-48058. (PMID: 27385003)
FEBS J. 2020 Apr;287(7):1323-1342. (PMID: 31858709)
J Steroid Biochem Mol Biol. 1999 Apr-Jun;69(1-6):211-25. (PMID: 10418995)
Antimicrob Agents Chemother. 2016 Apr 22;60(5):2664-70. (PMID: 26856844)
Chem Biol Interact. 2009 Mar 16;178(1-3):145-50. (PMID: 19013440)
Indian J Physiol Pharmacol. 2000 Oct;44(4):401-10. (PMID: 11214494)
J Dairy Sci. 2010 Oct;93(10):4613-24. (PMID: 20854995)
فهرسة مساهمة: Keywords: Alcoholic Liver disease; Aldo-keto reductases; Cancers; Promiscuity; Steroid synthesis
المشرفين على المادة: EC 1.1.1.- (Aldo-Keto Reductases)
تواريخ الأحداث: Date Created: 20240701 Date Completed: 20240701 Latest Revision: 20240702
رمز التحديث: 20240702
مُعرف محوري في PubMed: PMC11202113
DOI: 10.59249/VTBV6559
PMID: 38947111
قاعدة البيانات: MEDLINE
الوصف
تدمد:1551-4056
DOI:10.59249/VTBV6559